Literature DB >> 11396438

Blood purification in the intensive care unit: evolving concepts.

R Bellomo1, C Ronco.   

Abstract

Until relatively recently surgeons were familiar with the concept that some of their patients admitted to the intensive care unit require dialysis to deal with the development of severe acute renal failure. Under such circumstances the nephrology team would then attend the patient and take over that aspect of management. More recently, however, this situation has undergone a significant evolution because of the advent of continuous renal replacement therapy (CRRT). First introduced as "last ditch" therapy in the most critically ill patients who were hemodynamically intolerant of hemodialysis, CRRT has become more and more widely used. It is now the dominant form of artificial renal support in Australia and close to being the dominant treatment of the severe acute renal failure of critical illness in most European countries. The use of CRRT in the United States is rapidly growing. The arrival of CRRT has also renewed interest in the wider concept of blood purification during critical illness. Experimental and preliminary human data suggest that such blood purification therapies may indeed have beneficial immunomodulatory effects. Accordingly, CRRT is now being considered as a potential adjuvant treatment of septic shock and has even moved into the operating room as a tool for antiinflammatory therapy and volume control. The intensivist-surgeon and the general surgeon need to be aware of and understand these developments in extracorporeal therapy if they wish to make the full armamentarium of modern treatment available to their sickest patients.

Entities:  

Mesh:

Year:  2001        PMID: 11396438     DOI: 10.1007/s002680020030

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  6 in total

1.  ACUsmart Continuous Renal Replacement Therapy Platform: Multicenter Pilot Study for Technical and Clinical Assessment (A.M.P. Study).

Authors:  Mauro Neri; Anna Lorenzin; Massimo de Cal; Alessandra Brendolan; Nicola Marchionna; Sara Samoni; Monica Zanella; Silvia De Rosa; Francesca Martino; Zaccaria Ricci; Javier Maynar; Georg Auzinger; Gianluca Villa; Didier Payen; Michael Joannidis; Claudio Ronco
Journal:  Blood Purif       Date:  2019-02-01       Impact factor: 2.614

Review 2.  Continuous renal replacement therapies: a brief primer for the neurointensivist.

Authors:  Pritesh Patel; Veena Nandwani; Paul J McCarthy; Steven A Conrad; L Keith Scott
Journal:  Neurocrit Care       Date:  2010-10       Impact factor: 3.210

3.  Intermittent high permeability hemofiltration in septic patients with acute renal failure.

Authors:  Stanislao Morgera; Jens Rocktäschel; Michael Haase; Christian Lehmann; Christian von Heymann; Sabine Ziemer; Friedrich Priem; Berthold Hocher; Hermann Göhl; Wolfgang J Kox; Hans-W Buder; Hans-H Neumayer
Journal:  Intensive Care Med       Date:  2003-09-03       Impact factor: 17.440

4.  Continuous hemodiafiltration with PMMA Hemofilter in the treatment of patients with septic shock.

Authors:  Taka-Aki Nakada; Shigeto Oda; Ken-Ichi Matsuda; Tomohito Sadahiro; Masataka Nakamura; Ryuzo Abe; Hiroyuki Hirasawa
Journal:  Mol Med       Date:  2008 May-Jun       Impact factor: 6.354

5.  Broad adsorption of sepsis-related PAMP and DAMP molecules, mycotoxins, and cytokines from whole blood using CytoSorb® sorbent porous polymer beads.

Authors:  Maryann C Gruda; Karl-Gustav Ruggeberg; Pamela O'Sullivan; Tamaz Guliashvili; Andrew R Scheirer; Thomas D Golobish; Vincent J Capponi; Phillip P Chan
Journal:  PLoS One       Date:  2018-01-25       Impact factor: 3.240

Review 6.  Expanded haemodialysis: from operational mechanism to clinical results.

Authors:  Claudio Ronco; Nicola Marchionna; Alessandra Brendolan; Mauro Neri; Anna Lorenzin; Armando J Martínez Rueda
Journal:  Nephrol Dial Transplant       Date:  2018-10-01       Impact factor: 5.992

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.